Metraipolis › archive › dc_35a351bca397

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study — Europe PMC PMID:41544219

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41544219
DOI
10.1182/bloodadvances.2025017489
License (as archived)
solo-consultazione
Archived
2026-10-15T17:19:04.202Z
SHA-256 of the archived text
36ed6a7986a0eb98171526834d3a26d4c2f763e496f1d5b9d4151885fb010930
Stable URL of this page
https://metraipolis.com/documento/dc_35a351bca397

How to cite

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study — Europe PMC PMID:41544219 — Europe PMC (en), https://europepmc.org/article/MED/41544219 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_35a351bca397 (Metraipolis archive dc_35a351bca397, sha256 36ed6a7986a0eb98171526834d3a26d4c2f763e496f1d5b9d4151885fb010930)
BibTeX
@misc{dc35a351bca397,
  title = {Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study — Europe PMC PMID:41544219},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41544219},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_35a351bca397; sha256 36ed6a7986a0eb98171526834d3a26d4c2f763e496f1d5b9d4151885fb010930},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41544219. Agents can read the archived copy with the MCP tool read_document.